IL27A_MOUSE
ID IL27A_MOUSE Reviewed; 234 AA.
AC Q8K3I6;
DT 26-FEB-2008, integrated into UniProtKB/Swiss-Prot.
DT 01-OCT-2002, sequence version 1.
DT 03-AUG-2022, entry version 125.
DE RecName: Full=Interleukin-27 subunit alpha;
DE Short=IL-27 subunit alpha;
DE Short=IL-27-A;
DE Short=IL27-A;
DE AltName: Full=p28;
DE Flags: Precursor;
GN Name=Il27; Synonyms=Il27a;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC Murinae; Mus; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, TISSUE
RP SPECIFICITY, AND SUBUNIT.
RC STRAIN=NZB;
RX PubMed=12121660; DOI=10.1016/s1074-7613(02)00324-2;
RA Pflanz S., Timans J.C., Cheung J., Rosales R., Kanzler H., Gilbert J.,
RA Hibbert L., Churakova T., Travis M., Vaisberg E., Blumenschein W.M.,
RA Mattson J.D., Wagner J.L., To W., Zurawski S., McClanahan T.K.,
RA Gorman D.M., Bazan J.F., de Waal Malefyt R., Rennick D., Kastelein R.A.;
RT "IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces
RT proliferation of naive CD4(+) T cells.";
RL Immunity 16:779-790(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC STRAIN=C57BL/6J; TISSUE=Bone marrow;
RX PubMed=16141072; DOI=10.1126/science.1112014;
RA Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT "The transcriptional landscape of the mammalian genome.";
RL Science 309:1559-1563(2005).
RN [3]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC TISSUE=Brain;
RX PubMed=15489334; DOI=10.1101/gr.2596504;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA project:
RT the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
RN [4]
RP FUNCTION.
RX PubMed=14565860; DOI=10.1089/10799900360708632;
RA Hibbert L., Pflanz S., De Waal Malefyt R., Kastelein R.A.;
RT "IL-27 and IFN-alpha signal via Stat1 and Stat3 and induce T-Bet and IL-
RT 12Rbeta2 in naive T cells.";
RL J. Interferon Cytokine Res. 23:513-522(2003).
RN [5]
RP FUNCTION.
RX PubMed=14657353; DOI=10.1073/pnas.2536517100;
RA Lucas S., Ghilardi N., Li J., de Sauvage F.J.;
RT "IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-
RT dependent and -independent mechanisms.";
RL Proc. Natl. Acad. Sci. U.S.A. 100:15047-15052(2003).
RN [6]
RP FUNCTION.
RX PubMed=14871851; DOI=10.1158/0008-5472.can-03-2084;
RA Hisada M., Kamiya S., Fujita K., Belladonna M.L., Aoki T., Koyanagi Y.,
RA Mizuguchi J., Yoshimoto T.;
RT "Potent antitumor activity of interleukin-27.";
RL Cancer Res. 64:1152-1156(2004).
RN [7]
RP FUNCTION.
RX PubMed=15585838; DOI=10.4049/jimmunol.173.12.7170;
RA Salcedo R., Stauffer J.K., Lincoln E., Back T.C., Hixon J.A., Hahn C.,
RA Shafer-Weaver K., Malyguine A., Kastelein R., Wigginton J.M.;
RT "IL-27 mediates complete regression of orthotopic primary and metastatic
RT murine neuroblastoma tumors: role for CD8+ T cells.";
RL J. Immunol. 173:7170-7182(2004).
RN [8]
RP INDUCTION.
RX PubMed=15804443; DOI=10.1016/j.brainres.2005.01.100;
RA Sonobe Y., Yawata I., Kawanokuchi J., Takeuchi H., Mizuno T., Suzumura A.;
RT "Production of IL-27 and other IL-12 family cytokines by microglia and
RT their subpopulations.";
RL Brain Res. 1040:202-207(2005).
RN [9]
RP FUNCTION.
RX PubMed=15688376; DOI=10.1002/ijc.20848;
RA Chiyo M., Shimozato O., Yu L., Kawamura K., Iizasa T., Fujisawa T.,
RA Tagawa M.;
RT "Expression of IL-27 in murine carcinoma cells produces antitumor effects
RT and induces protective immunity in inoculated host animals.";
RL Int. J. Cancer 115:437-442(2005).
RN [10]
RP FUNCTION.
RX PubMed=16034109; DOI=10.4049/jimmunol.175.3.1686;
RA Morishima N., Owaki T., Asakawa M., Kamiya S., Mizuguchi J., Yoshimoto T.;
RT "Augmentation of effector CD8+ T cell generation with enhanced granzyme B
RT expression by IL-27.";
RL J. Immunol. 175:1686-1693(2005).
RN [11]
RP FUNCTION.
RX PubMed=16365415; DOI=10.4049/jimmunol.176.1.237;
RA Villarino A.V., Stumhofer J.S., Saris C.J.M., Kastelein R.A.,
RA de Sauvage F.J., Hunter C.A.;
RT "IL-27 limits IL-2 production during Th1 differentiation.";
RL J. Immunol. 176:237-247(2006).
RN [12]
RP FUNCTION.
RX PubMed=16493033; DOI=10.4049/jimmunol.176.5.2773;
RA Owaki T., Asakawa M., Kamiya S., Takeda K., Fukai F., Mizuguchi J.,
RA Yoshimoto T.;
RT "IL-27 suppresses CD28-mediated IL-2 production through suppressor of
RT cytokine signaling 3.";
RL J. Immunol. 176:2773-2780(2006).
RN [13]
RP FUNCTION.
RX PubMed=16751375; DOI=10.4049/jimmunol.176.12.7317;
RA Shimizu M., Shimamura M., Owaki T., Asakawa M., Fujita K., Kudo M.,
RA Iwakura Y., Takeda Y., Luster A.D., Mizuguchi J., Yoshimoto T.;
RT "Antiangiogenic and antitumor activities of IL-27.";
RL J. Immunol. 176:7317-7324(2006).
RN [14]
RP FUNCTION.
RX PubMed=17015723; DOI=10.4049/jimmunol.177.8.5377;
RA Yoshimura T., Takeda A., Hamano S., Miyazaki Y., Kinjyo I., Ishibashi T.,
RA Yoshimura A., Yoshida H.;
RT "Two-sided roles of IL-27: induction of Th1 differentiation on naive CD4+ T
RT cells versus suppression of proinflammatory cytokine production including
RT IL-23-induced IL-17 on activated CD4+ T cells partially through STAT3-
RT dependent mechanism.";
RL J. Immunol. 177:5377-5385(2006).
RN [15]
RP FUNCTION.
RX PubMed=17114427; DOI=10.4049/jimmunol.177.11.7579;
RA Owaki T., Asakawa M., Fukai F., Mizuguchi J., Yoshimoto T.;
RT "IL-27 induces Th1 differentiation via p38 MAPK/T-bet- and intercellular
RT adhesion molecule-1/LFA-1/ERK1/2-dependent pathways.";
RL J. Immunol. 177:7579-7587(2006).
RN [16]
RP MOUSE MODEL OF EXPERIMENTAL AUTOIMMUNE ENCEPHALITIS, AND FUNCTION.
RX PubMed=16906167; DOI=10.1038/ni1375;
RA Batten M., Li J., Yi S., Kljavin N.M., Danilenko D.M., Lucas S., Lee J.,
RA de Sauvage F.J., Ghilardi N.;
RT "Interleukin 27 limits autoimmune encephalomyelitis by suppressing the
RT development of interleukin 17-producing T cells.";
RL Nat. Immunol. 7:929-936(2006).
RN [17]
RP MOUSE MODEL OF EXPERIMENTAL AUTOIMMUNE ENCEPHALITIS, FUNCTION, AND
RP INDUCTION.
RX PubMed=16906166; DOI=10.1038/ni1376;
RA Stumhofer J.S., Laurence A., Wilson E.H., Huang E., Tato C.M.,
RA Johnson L.M., Villarino A.V., Huang Q., Yoshimura A., Sehy D.,
RA Saris C.J.M., O'Shea J.J., Hennighausen L., Ernst M., Hunter C.A.;
RT "Interleukin 27 negatively regulates the development of interleukin 17-
RT producing T helper cells during chronic inflammation of the central nervous
RT system.";
RL Nat. Immunol. 7:937-945(2006).
RN [18]
RP FUNCTION.
RX PubMed=17549733; DOI=10.1002/eji.200636896;
RA Neufert C., Becker C., Wirtz S., Fantini M.C., Weigmann B., Galle P.R.,
RA Neurath M.F.;
RT "IL-27 controls the development of inducible regulatory T cells and Th17
RT cells via differential effects on STAT1.";
RL Eur. J. Immunol. 37:1809-1816(2007).
RN [19]
RP INDUCTION.
RX PubMed=17548596; DOI=10.4049/jimmunol.178.12.7607;
RA Molle C., Nguyen M., Flamand V., Renneson J., Trottein F., De Wit D.,
RA Willems F., Goldman M., Goriely S.;
RT "IL-27 synthesis induced by TLR ligation critically depends on IFN
RT regulatory factor 3.";
RL J. Immunol. 178:7607-7615(2007).
RN [20]
RP MOUSE MODEL OF EXPERIMENTAL AUTOIMMUNE ENCEPHALITIS, AND INDUCTION.
RX PubMed=17709543; DOI=10.4049/jimmunol.179.5.3268;
RA Fitzgerald D.C., Ciric B., Touil T., Harle H., Grammatikopolou J.,
RA Das Sarma J., Gran B., Zhang G.-X., Rostami A.;
RT "Suppressive effect of IL-27 on encephalitogenic Th17 cells and the
RT effector phase of experimental autoimmune encephalomyelitis.";
RL J. Immunol. 179:3268-3275(2007).
RN [21]
RP REVIEW.
RX PubMed=17294231; DOI=10.1007/s00109-007-0164-7;
RA Batten M., Ghilardi N.;
RT "The biology and therapeutic potential of interleukin 27.";
RL J. Mol. Med. 85:661-672(2007).
RN [22]
RP INDUCTION.
RX PubMed=17727629; DOI=10.1111/j.1471-4159.2007.04875.x;
RA Xu J., Racke M.K., Drew P.D.;
RT "Peroxisome proliferator-activated receptor-alpha agonist fenofibrate
RT regulates IL-12 family cytokine expression in the CNS: relevance to
RT multiple sclerosis.";
RL J. Neurochem. 103:1801-1810(2007).
CC -!- FUNCTION: Associates with EBI3 to form the IL-27 interleukin, a
CC heterodimeric cytokine which functions in innate immunity. IL-27 has
CC pro- and anti-inflammatory properties, that can regulate T-helper cell
CC development, suppress T-cell proliferation, stimulate cytotoxic T-cell
CC activity, induce isotype switching in B-cells, and that has diverse
CC effects on innate immune cells. Among its target cells are CD4 T-helper
CC cells which can differentiate in type 1 effector cells (TH1), type 2
CC effector cells (TH2) and IL17 producing helper T-cells (TH17). It
CC drives rapid clonal expansion of naive but not memory CD4 T-cells. It
CC also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-
CC gamma production of naive CD4 T-cells, binds to the cytokine receptor
CC WSX-1/TCCR which appears to be required but not sufficient for IL-27-
CC mediated signal transduction. IL-27 potentiate the early phase of TH1
CC response and suppress TH2 and TH17 differentiation. It induces the
CC differentiation of TH1 cells via two distinct pathways, p38
CC MAPK/TBX21- and ICAM1/ITGAL/ERK-dependent pathways. It also induces
CC STAT1, STAT3, STAT4 and STAT5 phosphorylation and activates TBX21/T-Bet
CC via STAT1 with resulting IL12RB2 up-regulation, an event crucial to TH1
CC cell commitment. It suppresses the expression of GATA3, the inhibitor
CC TH1 cells development. In CD8 T-cells, it activates STATs as well as
CC GZMB. IL-27 reveals to be a potent inhibitor of TH17 cell development
CC and of IL-17 production. Indeed IL27 alone is also able to inhibit the
CC production of IL17 by CD4 and CD8 T-cells. While IL-27 suppressed the
CC development of pro-inflammatory Th17 cells via STAT1, it inhibits the
CC development of anti-inflammatory inducible regulatory T-cells, iTreg,
CC independently of STAT1. IL-27 has also an effect on cytokine
CC production, it suppresses pro-inflammatory cytokine production such as
CC IL2, IL4, IL5 and IL6 and activates suppressors of cytokine signaling
CC such as SOCS1 and SOCS3. Apart from suppression of cytokine production,
CC IL-27 also antagonizes the effects of some cytokines such as IL6
CC through direct effects on T-cells. Another important role of IL-27 is
CC its antitumor activity as well as its antiangiogenic activity with
CC activation of production of antiangiogenic chemokines such as IP-
CC 10/CXCL10 and MIG/CXCL9. {ECO:0000269|PubMed:12121660,
CC ECO:0000269|PubMed:14565860, ECO:0000269|PubMed:14657353,
CC ECO:0000269|PubMed:14871851, ECO:0000269|PubMed:15585838,
CC ECO:0000269|PubMed:15688376, ECO:0000269|PubMed:16034109,
CC ECO:0000269|PubMed:16365415, ECO:0000269|PubMed:16493033,
CC ECO:0000269|PubMed:16751375, ECO:0000269|PubMed:16906166,
CC ECO:0000269|PubMed:16906167, ECO:0000269|PubMed:17015723,
CC ECO:0000269|PubMed:17114427, ECO:0000269|PubMed:17549733}.
CC -!- SUBUNIT: Heterodimer with EBI3; not disulfide-linked. This heterodimer
CC is known as interleukin IL-27. {ECO:0000269|PubMed:12121660}.
CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:12121660}.
CC Note=Poorly secreted without coexpression of EBI3.
CC -!- TISSUE SPECIFICITY: Expressed in macrophages and dendritic cells.
CC {ECO:0000269|PubMed:12121660}.
CC -!- INDUCTION: By LPS and Interferon gamma in primary astrocytes and
CC microglia. Induced by Toll-like receptor ligand in dendritic cells.
CC Inhibited by PPAR-alpha agonist such as fenofibrate and produced by
CC TNF-alpha in microglia. {ECO:0000269|PubMed:15804443,
CC ECO:0000269|PubMed:16906166, ECO:0000269|PubMed:17548596,
CC ECO:0000269|PubMed:17709543, ECO:0000269|PubMed:17727629}.
CC -!- PTM: O-glycosylated. {ECO:0000250}.
CC -!- MISCELLANEOUS: In mouse models of experimental autoimmune encephalitis
CC (EAE) induced by Toxoplasma Gondi infection, brain levels of IL-27 are
CC massively increased. Deficiency of IL-27 receptors in this mouse model
CC with EAE induces development of a more severe neuroinflammation than in
CC wild-type mice with EAE. This excessive neuroinflammation is associated
CC with increased numbers of TH17 cells in the central nervous system
CC (CNS). Continuous administration of IL-27 to EAE mice produces a strong
CC suppressive effect on active EAE, with reduced CNS infiltration of TH17
CC cells and TH17 cells activity.
CC -!- MISCELLANEOUS: Mice injected with B16F10 tumor cells develop tumors and
CC lung metastasis. In mice injected with B16F10 tumor cells stably
CC transfected with IL-27, tumor cells grow much more slowly and the
CC number of pulmonary metastasis is markedly reduced. IL-27 exhibits a
CC strong antitumor activity as well as antiangiogenic activity with
CC massive decreased of microvessels density in lung metastasis.
CC Similarly, mice injected with C26 colon tumor cells transfected with
CC IL-27 acquire tumor-specific protective activity and exhibit minimal
CC tumor growth with enhanced IFN-gamma production. This antitumor
CC activity is abolished in TBX21-deficient mice. Neuroblastoma cells
CC overexpressing IL-27 also demonstrate markedly delayed growth; This
CC tumor regression appears to be dependent on CD8 cells.
CC -!- SIMILARITY: Belongs to the IL-6 superfamily. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AY099297; AAM34499.1; -; mRNA.
DR EMBL; AK152114; BAE30958.1; -; mRNA.
DR EMBL; AK153466; BAE32017.1; -; mRNA.
DR EMBL; BC119402; AAI19403.1; -; mRNA.
DR CCDS; CCDS21835.1; -.
DR RefSeq; NP_663611.1; NM_145636.1.
DR AlphaFoldDB; Q8K3I6; -.
DR SMR; Q8K3I6; -.
DR IntAct; Q8K3I6; 2.
DR STRING; 10090.ENSMUSP00000054637; -.
DR GlyGen; Q8K3I6; 1 site.
DR PhosphoSitePlus; Q8K3I6; -.
DR PaxDb; Q8K3I6; -.
DR PRIDE; Q8K3I6; -.
DR Antibodypedia; 13022; 606 antibodies from 39 providers.
DR DNASU; 246779; -.
DR Ensembl; ENSMUST00000058429; ENSMUSP00000054637; ENSMUSG00000044701.
DR GeneID; 246779; -.
DR KEGG; mmu:246779; -.
DR UCSC; uc009jsc.1; mouse.
DR CTD; 246778; -.
DR MGI; MGI:2384409; Il27.
DR VEuPathDB; HostDB:ENSMUSG00000044701; -.
DR eggNOG; ENOG502SVMM; Eukaryota.
DR GeneTree; ENSGT00390000018206; -.
DR HOGENOM; CLU_102031_0_0_1; -.
DR InParanoid; Q8K3I6; -.
DR OMA; PAQVSWP; -.
DR OrthoDB; 1356544at2759; -.
DR PhylomeDB; Q8K3I6; -.
DR TreeFam; TF337498; -.
DR Reactome; R-MMU-9020956; Interleukin-27 signaling.
DR BioGRID-ORCS; 246779; 2 hits in 72 CRISPR screens.
DR ChiTaRS; Il27; mouse.
DR PRO; PR:Q8K3I6; -.
DR Proteomes; UP000000589; Chromosome 7.
DR RNAct; Q8K3I6; protein.
DR Bgee; ENSMUSG00000044701; Expressed in granulocyte and 13 other tissues.
DR GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR GO; GO:0005829; C:cytosol; TAS:Reactome.
DR GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR GO; GO:0005615; C:extracellular space; IDA:MGI.
DR GO; GO:0005125; F:cytokine activity; IEA:UniProtKB-KW.
DR GO; GO:0045523; F:interleukin-27 receptor binding; IDA:MGI.
DR GO; GO:0005102; F:signaling receptor binding; IDA:MGI.
DR GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR GO; GO:0002230; P:positive regulation of defense response to virus by host; IDA:MGI.
DR GO; GO:0032729; P:positive regulation of interferon-gamma production; ISO:MGI.
DR GO; GO:0042129; P:regulation of T cell proliferation; IDA:MGI.
DR GO; GO:0045625; P:regulation of T-helper 1 cell differentiation; ISO:MGI.
DR GO; GO:0140459; P:response to Gram-positive bacterium; IEA:Ensembl.
DR Gene3D; 1.20.1250.10; -; 1.
DR InterPro; IPR009079; 4_helix_cytokine-like_core.
DR InterPro; IPR026207; IL-27_alpha.
DR PANTHER; PTHR20879; PTHR20879; 1.
PE 1: Evidence at protein level;
KW Cytokine; Glycoprotein; Immunity; Inflammatory response; Innate immunity;
KW Reference proteome; Secreted; Signal.
FT SIGNAL 1..28
FT /evidence="ECO:0000255"
FT CHAIN 29..234
FT /note="Interleukin-27 subunit alpha"
FT /id="PRO_0000320140"
FT REGION 160..185
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT CARBOHYD 85
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000255"
SQ SEQUENCE 234 AA; 26542 MW; DB33E7EC8AB4D0DA CRC64;
MGQVTGDLGW RLSLLLLPLL LVQAGSWGFP TDPLSLQELR REFTVSLYLA RKLLSEVQGY
VHSFAESRLP GVNLDLLPLG YHLPNVSLTF QAWHHLSDSE RLCFLATTLR PFPAMLGGLG
TQGTWTSSER EQLWAMRLDL RDLHRHLRFQ VLAAGFKCSK EEEDKEEEEE EEEEEKKLPL
GALGGPNQVS SQVSWPQLLY TYQLLHSLEL VLSRAVRDLL LLSLPRRPGS AWDS
